About the Company
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KLDO News
Kaleido Biosciences Inc KLDO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Kaleido Biosciences (OTC: KLDO)
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve ...
Flagship Ventures Fund 2007, L.P.'s Net Worth
Who is Flagship Ventures Fund 2007, L.P.? Flagship Ventures Fund 2007, L.P. has an estimated net worth of $280 Million. This is based on reported shares across multiple companies, which include ...
Flagship Ventures 2007 General Partner LLC's Net Worth
Who is Flagship Ventures 2007 General Partner LLC? Flagship Ventures 2007 General Partner LLC has an estimated net worth of $280 Million. This is based on reported shares across multiple companies ...
Kaleido Japan Inc.
Kaleido Japan Inc. was founded in 2011 and operates in Tokyo, Japan. The company engages in the sector 'Construction' (ISIC: F). The construction industry, which can be divided into several ...
Pacira BioSciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Castle Biosciences, Inc. (NASDAQ:CSTL): Are Analysts Optimistic?
With the business potentially at an important milestone, we thought we'd take a closer look at Castle Biosciences, Inc.'s (NASDAQ:CSTL) future prospects. Castle Biosciences, Inc., a commercial ...
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.
CTKB Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and ...
Kaleido Biosciences, Inc. (KLDO)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...